Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 25Rectal Neoplasms 23Esophageal Neoplasms 22Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Glioblastoma 16Pancreatic Neoplasms 14Lung Neoplasms 14Head and Neck Neoplasms 12Colorectal Neoplasms 11Sarcoma 10Brain Neoplasms 10Neoplasms 9Colonic Neoplasms 8Adenocarcinoma Of Esophagus 7Melanoma 6Glioma 6Esophageal Squamous Cell Carcinoma 6Ovarian Neoplasms 5Oropharyngeal Neoplasms 5Hypopharyngeal Neoplasms 5Carcinoma, Ovarian Epithelial 5Adenocarcinoma of Lung 5Prostatic Neoplasms 4Mouth Neoplasms 4Gliosarcoma 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Squamous Cell 4

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unresectable Non-small Cell Lung Cancer × Surgical Procedures, Operative × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡